Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

PHASE2CompletedINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

April 5, 2006

Primary Completion Date

June 1, 2007

Study Completion Date

June 19, 2007

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix vaccine

All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.

BIOLOGICAL

Engerix-B vaccine

All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule

Trial Locations (5)

GSK Investigational Site, Rauma

GSK Investigational Site, Tampere

GSK Investigational Site, Kouvola

GSK Investigational Site, Kotka

GSK Investigational Site, Mikkeli